Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer
- Saturday, September 28, 2019, 2:02
- Business
- Add a comment
BOTHELL, Wash. and TOKYO, Sept. 28, 2019 /PRNewswire/ — Seattle Genetics, Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced initial results from the phase 1 clinical trial EV-103. Forty-five patients were…
About the Author
adminasapcorp has written 39592 stories on this site.